6533b855fe1ef96bd12b06f0

RESEARCH PRODUCT

Cardiovascular Damage Induced by Anti-BCR-ABL TKIs

Giuseppina NovoFausto J. PintoManuela FiuzaDaniela Di Lisi

subject

Oncologymedicine.medical_specialtyCardiotoxicitybusiness.industryPonatinibImatinibDasatinibchemistry.chemical_compoundchemistryNilotinibhemic and lymphatic diseasesInternal medicinemedicineAdverse effectbusinessBosutinibTyrosine kinasemedicine.drug

description

Anti-BCR-ABL TKIs (tyrosine kinase inhibitors) are drugs that inhibit BCR ABL tyrosine. They are used especially in the treatment of hematological cancer and gastrointestinal stromal tumors (GIST). Anti-BCR-ABL TKIs include first (imatinib), second (nilotinib, dasatinib, bosutinib) and third-generation drugs (ponatinib). Especially second- and third-generation drugs can cause cardiovascular complications such as arterial thrombosis, myocardial ischemia, peripheral arterial diseases, QTc prolongation, and pulmonary hypertension. Nilotinib and ponatinib can cause thrombotic arterial events with various mechanisms. Particularly dasatinib can cause pulmonary hypertension. Compared to conventional chemotherapy, myocardial dysfunction was found in a smaller number of cases. In this chapter, we will illustrate cardiovascular adverse effects induced by anti-BCR-ABL TKIs, the main mechanisms that could explain such effects, and the influence played by cardiovascular risk factors. It is essential for both cardiologists and oncologists to know these issues in order to develop appropriate monitoring and apply preventive strategies to avoid the occurrence of toxicity and the need of any premature interruption of the antineoplastic treatment.

yearjournalcountryeditionlanguage
2018-10-05
https://doi.org/10.1007/978-3-319-93402-0_6